Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
OM received a notice that insider John Brottem plans to sell 9,314 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the NASDAQ market. The filing lists an aggregate market value of $47,682.76 for these shares, compared with 18,153,090 shares of common stock outstanding.
The securities to be sold were acquired on 01/17/2026 through settlement of 17,997 vested restricted stock units as equity compensation for services rendered. The notice also reports that during the prior three months, Brottem sold 388 shares on 11/17/2025 for $1,784.80 and 244 shares on 01/07/2026 for $956.48. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.
BML Investment Partners, L.P., a Delaware limited partnership, reported a significant ownership position in Outset Medical, Inc. common stock on a Schedule 13G. BML disclosed beneficial ownership of 1,705,876 shares of common stock, representing 9.4% of the outstanding class.
BML reported shared voting and dispositive power over all 1,705,876 shares, with no sole voting or dispositive authority. The filing is signed by Braden M. Leonard on behalf of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P., and notes that Leonard is deemed an indirect owner of these shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Outset Medical, indicating a passive investment intent.
Outset Medical, Inc. director Karen Prange reported an equity grant in the form of restricted stock units. On January 9, 2026, she was awarded 18,667 RSUs, each representing a contingent right to receive one share of Outset Medical common stock at a price of $0.00 per unit.
The RSUs vest quarterly over three years, conditioned on her continued service with the company through each applicable vesting date. Following this grant, she beneficially owns 18,667 shares of common stock directly.
Outset Medical, Inc. director reports no beneficial ownership. Karen Prange, identified as a director of Outset Medical, Inc. (symbol OM), filed an initial statement of beneficial ownership of securities as of 01/09/2026. The filing states that no securities are beneficially owned, and both the non-derivative and derivative securities tables contain no holdings. The form is filed by a single reporting person and includes a power of attorney authorizing execution of the filing on her behalf.
Outset Medical, Inc. reported that it issued a press release with expected revenue for the fourth quarter and full year ended December 31, 2025, noting that this financial information is preliminary, unaudited and may change as closing and audit processes are completed. The company also furnished an updated investor presentation.
Board member Andrea Saia resigned effective January 9, 2026, and the company stated her departure was not due to any disagreement on operations, policies or practices. The Board appointed Karen Prange as a new independent director and Compensation Committee member, filling the vacancy as a class III director with a term running until the 2026 annual meeting. In connection with her appointment, Prange will receive an initial grant of 18,667 restricted stock units that vest quarterly over three years and an annual grant of 10,667 restricted stock units, subject to the company’s non‑employee director compensation policy.
Outset Medical executive Marc Nash reported a small, tax-related stock sale. On January 7, 2026, he sold 108 shares of Outset Medical common stock at $4.27 per share.
According to the footnote, the sale was required to cover tax withholding obligations tied to 289 shares underlying performance stock units that were earned based on performance criteria as of December 31, 2024 or January 6, 2025 and that vested and were released on January 6, 2025. The transaction was executed as a "sell to cover" and is described as not a discretionary trade by Nash.
After this sale, Nash directly beneficially owns 48,160 shares of Outset Medical common stock.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 224 shares of common stock on 01/07/2026 at a price of $4.27 per share. After this transaction, he beneficially owned 46,271 shares directly.
The filing explains that the sale was a required "sell to cover" transaction to satisfy tax withholding obligations tied to 447 shares of common stock underlying performance stock units that had been earned and vested, and it did not represent a discretionary trade by Brottem.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported a small sale of company stock that was made only to cover taxes. On January 7, 2026, she sold 1,795 shares of common stock at $4.27 per share in a transaction coded “S,” described as a “sell to cover” for tax withholding related to previously earned PSUs. According to the disclosure, this sale was required to satisfy tax obligations and “does not represent a discretionary trade.”
Following the sale, Trigg beneficially owned 119,617 shares of common stock directly, plus 41,666 shares held indirectly through the Trigg 2002 Rev Trust and 584 shares held indirectly through the Trigg Family Trust.
OM filed a Rule 144 notice for a small planned stock sale. The filing covers the proposed sale of 108 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on or about 01/07/2026, with the shares listed for trading on NASDAQ. The aggregate market value of this planned sale is reported as $461.16, based on market prices at the time of the notice.
The seller acquired the stock on 01/06/2026 through settlement of 289 vested performance stock units from the issuer as equity compensation for services rendered. Over the prior three months, the same seller disposed of 247 common shares on 11/17/2025 for gross proceeds of $1,136.20. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about OM’s current or prospective operations.
OM insider Leslie Trigg filed a notice of proposed sale of common stock under Rule 144. The filing covers the planned sale of 1,795 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $7,664.65 and 18,153,090 shares of common stock shown as outstanding.
The shares to be sold are part of a larger 4,904-share grant of common stock acquired on 01/06/2026 via settlement of vested performance stock units as equity compensation for services rendered. The filing also notes that Trigg previously sold 916 shares of common stock on 11/17/2025 for gross proceeds of $4,213.60. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.